Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON)

• DOI: 10.1007/s00432-018-2713-6
• Publication Date: 2018-08-13T03:05:02Z
• Authors: Muhammad A. Memon; Burcak Karaca; Rasha Aboelhassan; Mohsen Barsoum; Mustafa Erman; Mert Basaran; Alper Sevinc; Djedi Hanene; Cassandra Slader; Virginia Pilipovic; Kerboua Esma; Bouzid Kamel
• Keywords: Adult; Male; Indazoles; Epidemiological study; Middle East; 03 medical and health sciences; 0302 clinical medicine; Africa, Northern; Drug Therapy; Humans; Real-world outcomes; Neoplasm Metastasis; Aged; Retrospective Studies; Aged, 80 and over; Sulfonamides; Radiotherapy; Pazopanib; Sarcoma; Soft tissue sarcomas; Middle Aged; 3. Good health; Pyrimidines; Surgical Procedures, Operative; Female

Soft tissue sarcomas (STS) are a heterogeneous group of rare mesenchymal neoplasms, accounting for < 1% of all newly diagnosed malignancies. These tumors can occur in almost any anatomic site though they most frequently occur in the extremities. The objective of the study was to describe the epidemiology, treatment paradigm, and real-world outcomes in the clinical management of metastatic STS (mSTS) in the Middle East and North Africa (MEA) region.MOON was an observational, multicenter, retrospective patient chart review study which included 200 patients with mSTS in the final analysis. The primary objective of the study is exploratory, so it is presented using descriptive statistics.At the time of presentation, 62.0% patients had metastatic disease, 27.5% had received only their primary diagnosis and 10.0% had experienced a local recurrence. The most frequent STS localizations were lower extremities (74%), trunk (28.5%) and upper extremities (10.5%). Primary tumor was staged as T2b in the majority (60%) of patients. Surgical treatment was performed most often for the primary disease, whereas radiation therapy and chemotherapy were predominantly administered with palliative intent. A total of 38 patients received treatment with pazopanib. Thirteen adverse events (AEs) were attributed to pazopanib in eight patients.Adult patients treated for STS have al most equal gender ratio and mostly are middle aged. The majority of patients have metastatic disease and disease progression, and half of the patients died from the disease during the period of evaluation. This study obtained real-life data on the clinical management of STS in MEA countries which could be shared with the medical community.